31 drugmakers at high risk for bankruptcy in 2020

A BioPharma Dive analysis identified 31 drugmakers at a high risk of going bankrupt in the next 12 months. 

The analysis used data from CreditRiskMonitor, a firm that calculates the probability that a company will go bankrupt using a scale called a FRISK score. The score is based on factors such as credit agency ratings, crowdsourced subscriber data, stock volatility and financial ratios. 

The FRISK score is on a scale of 1 to 10 with 1 being the highest risk for bankruptcy and 10 being the lowest. The typical drugmaker has a FRISK score of 7, according to BioPharma Dive.

According to CreditRiskMonitor, FRISK scores have been 96 percent accurate in predicting bankruptcy. 

The following list includes drugmakers traded on major U.S. exchanges with current share prices above $1 and market values above $50 million. The market values and percent stock change are current through Nov. 16. 

          Drugmakers with a FRISK score of 1: 

  1. Amneal Pharmaceuticals 
  2. Akorn 
  3. Sorrento Therapeutics
  4. BioCryst Pharmaceuticals
  5. Novavax

    Drugmakers with a FRISK score of 2:

  6. Endo International
  7. Agenus 
  8. Clovis Oncology
  9. AMAG Pharmaceuticals 
  10. Puma Biotechnology
  11. MannKind
  12. Mallinckrodt
  13. La Jolla Pharmaceutical
  14. Aquestive Therapeutics 
  15. T2 Biosystems 
  16. Acorda Therapeutics 
  17. Assertio Therapeutics 
  18. Verastem 

    Drugmakers with a FRISK score of 3:

  19. Teva Pharmaceutical
  20. Bausch Health 
  21. ImmunoGen
  22. Seres Therapeutics
  23. CytomX Therapeutics 
  24. Avadel Pharmaceuticals
  25. Correvio Pharma
  26. Paratek Pharmaceuticals
  27. vTv Therapeutics 
  28. Adaptimmune Therapeutics 
  29. Neos Therapeutics 
  30. Aclaris Therapeutics
  31. Selecta Biosciences 

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars